Loading...
Efficacy of intracellular immune checkpoint-silenced DC vaccine
BACKGROUND. DC-based tumor vaccines have had limited clinical success thus far. SOCS1, a key inhibitor of inflammatory cytokine signaling, is an immune checkpoint regulator that limits DC immunopotency. METHODS. We generated a genetically modified DC (gmDC) vaccine to perform immunotherapy. The aden...
Na minha lista:
| Udgivet i: | JCI Insight |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Clinical Investigation
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5821183/ https://ncbi.nlm.nih.gov/pubmed/29415891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.98368 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|